Pharma & Bio
Lifestyle
“12 Million Patients, Only One Treatment”… Mezion Pharma Co., Ltd. Sets Sights on Rare Kidney Disease as It Moves Directly to FDA Phase 2 Trials
“We’ve been preparing for the post-Fontan era.” Following its treatment for a rare heart disease— Mezzion Pharma Co., Ltd.(140410)—is now positioning autosomal dominant polycystic kidney disease (ADPK…
Technology
Yoo Sang-gu, CEO of Glaseum: “We Expect Synergy with DaewonPharmaceutical’s Quadruple-Action Agent… We’re Focusing on Fat Loss”
The global obesity treatment market is evolving beyond glucagon-like peptide-1 (GLP-1)-based therapies toward triple- and quadruple-action drugs. Among domestic pharmaceutical companies, DaewonPharmac…
Technology
Nam Byung-ho, CEO of Herings: "Software Agreement with the Luxembourg Government... Expects Sales in Europe"
"Herrings has been selected as a partner for Luxembourg’s national disease management project. This achievement is believed to have been made possible thanks to the strong recommendation by Dr. Liners…
Technology
Will HASS Corp. Break Its Three-Year Sales Stagnation?… Challenging Zirconia’s Dominance with New Products
HASS Corp.(450330), which has seen stagnant sales for the past three years, is aiming to reshape the zirconia-based dental restoration materials market with a new lithium disilicate product that can b…
Lifestyle
EyeGene,Inc Begins Preparations to Export Recombinant Botox... Expectations for a Rebirth as a Profitable Company
EyeGene,Inc(185490)is set to reinvent itself as a company generating its own revenue, led by its next-generation botulinum toxin product based on recombinant DNA technology. The company plans to break…
Technology
Park Parma Strategy Expands Beyond Obesity and Diabetes to Cardiovascular Health… Attention on Potential Benefits for Alteogen Inc.
(Graphic: ChatGPT)
Global big pharma companies leading the obesity treatment market are expanding their pipelines into cardiovascular diseases. This move stems from the assessment that while gluca…
Lifestyle
Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
Technology
Lee Chi-won, CEO of Mediintech: “We’ll Turn the Tables on Japan’s Dominance in the Endoscopy Market with Physical AI”
A South Korean company has thrown down the gauntlet with innovative technology in the flexible endoscope market, where three Japanese firms—Olympus, Pentax, and Fujifilm—dominate more than 95% of the …
Lifestyle
BL Pharmtech Hits Daily Limit…Samchundang Pharm Falls [K-bio pulse]
Investors in the biopharmaceutical sector continued to show strong interest in BL Pharmtech on July 2, driving its stock to the daily upper limit. The surge was fueled by growing expectations of tangi…
Lifestyle
BL Pharmtech Hits Daily Price Limit as Results Take Shape… SAM CHUN DANG PHARM CO. LTD Falls [Bio Spotlight]
On the 2nd, shares of BL Pharmtech(065170)hit the daily price limit again as investor interest in the pharmaceutical and biotech sector continued. BL Pharmtech’s stock price rose on expectations that …